Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort-Reference-Cited by-同舟云学术

Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

Published:2011-12 Issue:12 Volume:6 Page:2011-2017
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yano Seiji,Yamada Tadaaki,Takeuchi Shinji,Tachibana Keisei,Minami Yuko,Yatabe Yasushi,Mitsudomi Tetsuya,Tanaka Hidenori,Kimura Tatsuo,Kudoh Shinzoh,Nokihara Hiroshi,Ohe Yuichiro,Yokota Jun,Uramoto Hidetaka,Yasumoto Kosei,Kiura Katsuyuki,Higashiyama Masahiko,Oda Makoto,Saito Haruhiro,Yoshida Junji,Kondoh Kazuya,Noguchi Masayuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

4. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer;Mitsudomi;Cancer Sci,2007

5. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors;Calvo;J Clin Oncol,2006

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts;Cancer Research Communications;2024-09-01

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer;Cancer Letters;2024-08

4. Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

5. Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Targeted Therapy in Lung Adenocarcinoma Cell Lines;Cancers;2024-07-08